Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pralnacasan inhibits proinflammatory cytokines IL-18, IL-1β , and IFN-γ. Pralnacasan is an effective, non-peptide, and orally active interleukin-1β converting enzyme inhibitor (Ki: 1.4 nM). Pralnacasan has the potential for osteoarthritis and rheumatoid arthritis treatment.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | Inquiry | $ 722.00 |
Description | Pralnacasan inhibits proinflammatory cytokines IL-18, IL-1β , and IFN-γ. Pralnacasan is an effective, non-peptide, and orally active interleukin-1β converting enzyme inhibitor (Ki: 1.4 nM). Pralnacasan has the potential for osteoarthritis and rheumatoid arthritis treatment. |
Targets&IC50 | IL-1β converting enzyme:1.4 nM (ki) |
In vivo | Pralnacasan treatment does not appear to affect the weight of the animals. Pralnacasan (0 -50 mg/kg; oral gavage; twice a day; for 6 weeks; female Balb/c mice) treatment decreases joint damage [1]. |
Synonyms | VX-740, HMR 3480 |
Molecular Weight | 523.54 |
Formula | C26H29N5O7 |
CAS No. | 192755-52-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Pralnacasan 192755-52-5 Others VX-740 HMR 3480 VX740 HMR-3480 HMR3480 VX 740 inhibitor inhibit